Suggested Remit: To appraise the clinical and cost effectiveness of nivolumab with platinum-based chemotherapy within its marketing authorisation for advanced unresectable, recurrent or metastatic oesophageal cancer that has not been previously treated.
 
Status In progress
Decision Selected
Process STA 2018
ID number 2712

Provisional Schedule

Expected publication 23 November 2022

Project Team

Project lead Shonagh D'Sylva

Email enquiries

Stakeholders

Companies sponsors Bristol-Myers Squibb (nivolumab, ipilimumab)
Others Department of Health and Social Care
  NHS England
  NHS Hillingdon CCG
  NHS Rushcliffe CCG
  Welsh Government
Patient carer groups Black Health Agency for Equality
  Cancer Black Care
  Cancer Equality
  Cancer 52
  Guts UK
  GIST Cancer UK
  Heartburn Cancer UK
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Ochre
  Oesophageal Patients Association
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
  British Association of Surgical Oncology
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society of Gastroenterology
  Cancer Research UK
  Primary Care Society for Gastroenterology
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Accord Healthcare (capecitabine, cisplatin, epirubicin, fluorouracil, oxaliplatin)
  Dr Reddy’s Laboratories (capecitabine)
  Fresenius Kabi (oxaliplatin)
  Glenmark Pharmaceuticals Europe (capecitabine)
  Hospira UK (cisplatin, fluorouracil, oxaliplatin)
  Medac GmbH (epirubicin, fluorouracil, oxaliplatin)
  Merck Sharp & Dohme (UK) (pembrolizumab)
  Morningside Healthcare (capecitabine)
  Mylan (epirubicin)
  Pfizer (cisplatin, epirubicin, fluorouracil, oxaliplatin)
  Sandoz (cisplatin)
  Seacross Pharmaceuticals (oxaliplatin)
  Sun Pharmaceutical Industries Europe (oxaliplatin)
  Teva (cisplatin, epirubicin)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Scottish Society of Gastroenterology
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
  Cochrane UK
  Genomics England
  Guts UK
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Oracle Cancer Trust

Timeline

Key events during the development of the guidance:

Date Update
13 January 2022 Invitation to participate
05 October 2021 As you will be aware The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712] and Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]. Please note that following on from information received from the company, these appraisals have been combined and will be appraised as one Single Technology Appraisal [ID2712]. The timelines have been revised and the appraisal is now anticipated to begin in mid- January 2022 when we will write to stakeholders about how they can get involved.
30 September 2020 - 28 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 January 2020 In progress. Topic is in progress

For further information on our processes and methods, please see our CHTE processes and methods manual